2026-04-28T19:07:43Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/618772024-12-16T07:27:16Zcom_10324_1133com_10324_931com_10324_894col_10324_1209

00925njm 22002777a 4500 dc Gutiérrez Abejón, Eduardo author Herrera Gómez, Francisco Magno author Pedrosa Naudín, M. Aránzazu author Tamayo Gómez, Eduardo author Álvarez González, Francisco Javier author 2022 Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS. Medicina, 2022, Vol. 58, Nº. 6, 829 1648-9144 https://uvadoc.uva.es/handle/10324/61877 10.3390/medicina58060829 829 6 Medicina 58 1648-9144 SARS-CoV-2 COVID-19 SARS (Disease) Syndromes Clinical findings Pharmacotherapy Survival Supervivencia Virology Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival